Fosun Pharma (600196.SH) subsidiary FCN-159 tablet included in breakthrough therapy program.

Zhijun Finance APP News, Fosun Pharma (600196.SH) announced that, according to the public announcement from the Drug Evaluation Center of the National Medical Products Administration (referred to as the "National Drug Administration"), the company's holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.'s FCN-159 tablet (application for registration category: chemical drugs category 1; hereinafter referred to as "the new drug") for the treatment of pediatric Langhans histiocytosis has been included in the breakthrough therapy drug program.